To avoid anti-kickback litigation with government, pharma companies need a defensible position on FMV assessments
Stephen Rothenberg, Numerof & Associates, Inc.
Advertisement
Articles by Stephen Rothenberg, Numerof & Associates, Inc.
Advertisement
Latest Updated Articles
- Defending Fair Market Value (FMV) Assessments
June 28th 2010
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
When Drug Pricing Collides With Politics
2
The End of the Traditional Launch: How JCA, HTA Evolution and Pricing Pressures Are Driving Continuous Evidence Generation
3
How CMS’ Final Negotiation Rule Treats New Drug Formulations
4
Idle US Capacity Could Anchor Generic Drug Reshoring, APIIC Says
5